Home / Intelligence / Case Studies / Early P&MA Forecasting Support for a Pipeline Asset
Trinity provided early P&MA forecasting support for a pipeline asset in development for several inflammatory conditions via secondary research.
Geographic Scope: 
Client Situation
The client wanted to uncover the optimal launch strategy for their pipeline asset by understanding the current and future landscape across several inflammatory diseases to support indication prioritization.
Trinity’s Solution
Trinity conducted secondary research into the clinical treatment algorithms and current pricing and market access (P&MA) landscape of 19 inflammatory diseases to understand the unmet need, level of competition, payer management, contracting and pricing benchmarks.
Trinity then ran a pipeline assessment to predict shifts within the landscape and evolution in P&MA benchmarks, and synthesized findings to deliver a comprehensive indication-by-indication achievable net pricing strategy for early P&MA forecasting inputs.
Deliverables
- Detailed XLS outlining current pricing and access status of competitor therapies including level of contracting and payer mix
- Pipeline analysis including likely price comparator, achievable net price and likely level of payer management
Project Outcomes & Impact
The key P&MA data that Trinity provided to inform inputs for the early P&MA forecast of the client’s pipeline asset enabled them to prioritize their development activities and launch strategy to optimize the commercial opportunity.
Related Intelligence
Blog
Joint Clinical Assessment in the EU: What Life Sciences Companies Need to Know
March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences, stakeholders gathered to explore the implications of this new regulatory framework and how to […]
Read More
Blog
Pricing and Access in Germany: Innovation and Strong Evidence Rewarded
Germany’s Medical Research Act (Medizinforschungsgesetz or MFG), which came into force on October 30, 2024, is a major legislative reform aimed at strengthening Germany’s position as an attractive environment for medical innovation and pharmaceutical development. The act provides for confidential negotiated drug pricing, incentives for local clinical trials, simplified clinical trial approvals and harmonization of […]
Read More
Blog
Seizing the Storm: Why Pharma Must Plan, Not Panic in Trump’s Second Term
The first 100 days of President Trump’s return to the White House have been anything but ordinary. With a true “Flood the Zone” strategy, there has been a flurry of executive orders, leadership reshuffles, and a re-assertion of executive power, which has signaled the administration is interested in seeing what policy options can “stick.” While […]
Read More